Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.57 |
| ▸ | MAG | P20916 | 5/20 | 0.56 |
| ▸ | SELL | P14151 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.53 |
| ▸ | CD22 | P20273 | 11/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883057 | 1.00 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL29437858 | 1.00 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL31309218 | 1.00 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL29397098 | 1.00 | SIGLEC7 (0.57) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL29410578 | 0.94 | SIGLEC7 (0.55) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL16298815 | 0.94 | SIGLEC7 (0.55) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL29352702 | 0.94 | SIGLEC7 (0.55) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL15177450 | 0.94 | SIGLEC7 (0.55) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL29732933 | 0.94 | SIGLEC7 (0.55) | SIGLEC7MAGSELLSELPNANP | |
| SCHEMBL17300136 | 0.93 | MAG (0.56) | SIGLEC7MAGSELLSELPNANP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752204-B2 | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | OBI PHARMA INC. (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20230056782-A1 | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | OBI PHARMA, INC. (TW) | 2023-02-23 | — | — | US | disclosed |
| CN-108472362-B | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof | 台湾浩鼎生技股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11236154-B2 | Carbohydrate antibodies, pharmaceutical compositions and uses thereof | OBI PHARMA INC. (TW) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752204-B2 | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | STT3A, STT3B, DDOST | SIGLEC7 9/4885MAG 503/4885SELL 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.